250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Paul O'Connor, Massimo Filippi, Barry Arnason, Giancarlo Comi, Stuart Cook, Douglas Goodin, Hans Peter Hartung, Douglas Jeffery, Ludwig Kappos, Francis Boateng, Vitali Filippov, Maria Groth, Volker Knappertz, Christian Kraus, Rupert Sandbrink, Christoph Pohl, Timon Bogumil

Research output: Contribution to journalArticle

318 Citations (Scopus)

Abstract

Background: The aim of the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial was to compare the efficacy, safety, and tolerability of 250 μg or 500 μg interferon beta-1b with glatiramer acetate for treating relapsing-remitting multiple sclerosis. Methods: Between November, 2003, and June, 2005, 2447 patients with relapsing-remitting multiple sclerosis were screened and 2244 patients were enrolled in this prospective, multicentre, randomised trial. Patients were randomly assigned 2:2:1 by block randomisation with regional stratification to receive one of two doses of interferon beta-1b (250 μg or 500 μg) subcutaneously every other day or 20 mg glatiramer acetate subcutaneously every day. The primary outcome was relapse risk, defined as new or recurrent neurological symptoms separated by at least 30 days from the preceding event and that lasted at least 24 h. Secondary outcomes were progression on the expanded disability status scale (EDSS) and change in T1-hypointense lesion volume. Clinical outcomes were assessed quarterly for 2·0-3·5 years; MRI was done at screening and annually thereafter. Analysis was by per protocol. This study is registered, number NCT00099502. Findings: We found no differences in relapse risk, EDSS progression, T1-hypointense lesion volume, or normalised brain volume among treatment groups. Flu-like symptoms were more common in patients treated with interferon beta-1b (p

Original languageEnglish
Pages (from-to)889-897
Number of pages9
JournalThe Lancet Neurology
Volume8
Issue number10
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Multicenter Studies
Recurrence
Random Allocation
Safety
Interferon beta-1b
Glatiramer Acetate
Brain
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Medicine(all)

Cite this

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis : a prospective, randomised, multicentre study. / O'Connor, Paul; Filippi, Massimo; Arnason, Barry; Comi, Giancarlo; Cook, Stuart; Goodin, Douglas; Hartung, Hans Peter; Jeffery, Douglas; Kappos, Ludwig; Boateng, Francis; Filippov, Vitali; Groth, Maria; Knappertz, Volker; Kraus, Christian; Sandbrink, Rupert; Pohl, Christoph; Bogumil, Timon.

In: The Lancet Neurology, Vol. 8, No. 10, 10.2009, p. 889-897.

Research output: Contribution to journalArticle

O'Connor, P, Filippi, M, Arnason, B, Comi, G, Cook, S, Goodin, D, Hartung, HP, Jeffery, D, Kappos, L, Boateng, F, Filippov, V, Groth, M, Knappertz, V, Kraus, C, Sandbrink, R, Pohl, C & Bogumil, T 2009, '250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study', The Lancet Neurology, vol. 8, no. 10, pp. 889-897. https://doi.org/10.1016/S1474-4422(09)70226-1
O'Connor, Paul ; Filippi, Massimo ; Arnason, Barry ; Comi, Giancarlo ; Cook, Stuart ; Goodin, Douglas ; Hartung, Hans Peter ; Jeffery, Douglas ; Kappos, Ludwig ; Boateng, Francis ; Filippov, Vitali ; Groth, Maria ; Knappertz, Volker ; Kraus, Christian ; Sandbrink, Rupert ; Pohl, Christoph ; Bogumil, Timon. / 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis : a prospective, randomised, multicentre study. In: The Lancet Neurology. 2009 ; Vol. 8, No. 10. pp. 889-897.
@article{9f97ed1f994e4be88bdb0c4f93531334,
title = "250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study",
abstract = "Background: The aim of the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial was to compare the efficacy, safety, and tolerability of 250 μg or 500 μg interferon beta-1b with glatiramer acetate for treating relapsing-remitting multiple sclerosis. Methods: Between November, 2003, and June, 2005, 2447 patients with relapsing-remitting multiple sclerosis were screened and 2244 patients were enrolled in this prospective, multicentre, randomised trial. Patients were randomly assigned 2:2:1 by block randomisation with regional stratification to receive one of two doses of interferon beta-1b (250 μg or 500 μg) subcutaneously every other day or 20 mg glatiramer acetate subcutaneously every day. The primary outcome was relapse risk, defined as new or recurrent neurological symptoms separated by at least 30 days from the preceding event and that lasted at least 24 h. Secondary outcomes were progression on the expanded disability status scale (EDSS) and change in T1-hypointense lesion volume. Clinical outcomes were assessed quarterly for 2·0-3·5 years; MRI was done at screening and annually thereafter. Analysis was by per protocol. This study is registered, number NCT00099502. Findings: We found no differences in relapse risk, EDSS progression, T1-hypointense lesion volume, or normalised brain volume among treatment groups. Flu-like symptoms were more common in patients treated with interferon beta-1b (p",
author = "Paul O'Connor and Massimo Filippi and Barry Arnason and Giancarlo Comi and Stuart Cook and Douglas Goodin and Hartung, {Hans Peter} and Douglas Jeffery and Ludwig Kappos and Francis Boateng and Vitali Filippov and Maria Groth and Volker Knappertz and Christian Kraus and Rupert Sandbrink and Christoph Pohl and Timon Bogumil",
year = "2009",
month = "10",
doi = "10.1016/S1474-4422(09)70226-1",
language = "English",
volume = "8",
pages = "889--897",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis

T2 - a prospective, randomised, multicentre study

AU - O'Connor, Paul

AU - Filippi, Massimo

AU - Arnason, Barry

AU - Comi, Giancarlo

AU - Cook, Stuart

AU - Goodin, Douglas

AU - Hartung, Hans Peter

AU - Jeffery, Douglas

AU - Kappos, Ludwig

AU - Boateng, Francis

AU - Filippov, Vitali

AU - Groth, Maria

AU - Knappertz, Volker

AU - Kraus, Christian

AU - Sandbrink, Rupert

AU - Pohl, Christoph

AU - Bogumil, Timon

PY - 2009/10

Y1 - 2009/10

N2 - Background: The aim of the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial was to compare the efficacy, safety, and tolerability of 250 μg or 500 μg interferon beta-1b with glatiramer acetate for treating relapsing-remitting multiple sclerosis. Methods: Between November, 2003, and June, 2005, 2447 patients with relapsing-remitting multiple sclerosis were screened and 2244 patients were enrolled in this prospective, multicentre, randomised trial. Patients were randomly assigned 2:2:1 by block randomisation with regional stratification to receive one of two doses of interferon beta-1b (250 μg or 500 μg) subcutaneously every other day or 20 mg glatiramer acetate subcutaneously every day. The primary outcome was relapse risk, defined as new or recurrent neurological symptoms separated by at least 30 days from the preceding event and that lasted at least 24 h. Secondary outcomes were progression on the expanded disability status scale (EDSS) and change in T1-hypointense lesion volume. Clinical outcomes were assessed quarterly for 2·0-3·5 years; MRI was done at screening and annually thereafter. Analysis was by per protocol. This study is registered, number NCT00099502. Findings: We found no differences in relapse risk, EDSS progression, T1-hypointense lesion volume, or normalised brain volume among treatment groups. Flu-like symptoms were more common in patients treated with interferon beta-1b (p

AB - Background: The aim of the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial was to compare the efficacy, safety, and tolerability of 250 μg or 500 μg interferon beta-1b with glatiramer acetate for treating relapsing-remitting multiple sclerosis. Methods: Between November, 2003, and June, 2005, 2447 patients with relapsing-remitting multiple sclerosis were screened and 2244 patients were enrolled in this prospective, multicentre, randomised trial. Patients were randomly assigned 2:2:1 by block randomisation with regional stratification to receive one of two doses of interferon beta-1b (250 μg or 500 μg) subcutaneously every other day or 20 mg glatiramer acetate subcutaneously every day. The primary outcome was relapse risk, defined as new or recurrent neurological symptoms separated by at least 30 days from the preceding event and that lasted at least 24 h. Secondary outcomes were progression on the expanded disability status scale (EDSS) and change in T1-hypointense lesion volume. Clinical outcomes were assessed quarterly for 2·0-3·5 years; MRI was done at screening and annually thereafter. Analysis was by per protocol. This study is registered, number NCT00099502. Findings: We found no differences in relapse risk, EDSS progression, T1-hypointense lesion volume, or normalised brain volume among treatment groups. Flu-like symptoms were more common in patients treated with interferon beta-1b (p

UR - http://www.scopus.com/inward/record.url?scp=69949098534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949098534&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(09)70226-1

DO - 10.1016/S1474-4422(09)70226-1

M3 - Article

C2 - 19729344

AN - SCOPUS:69949098534

VL - 8

SP - 889

EP - 897

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 10

ER -